Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G T Ho

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Mucosal Immunology|April 13, 2017
MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammationG-T Ho, R E Aird, B Liu, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)G T Ho, A Mowat, L Potts, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2009
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-upC W Lees, A I Ali, A I Thompson, et al.
Journal of Crohn'S & Colitis|November 17, 2020
Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel diseaseR Kalla, A T Adams, D Bergemalm, et al.
Journal of Crohn'S & Colitis|June 30, 2020
Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel DiseaseR Kalla, A T Adams, N T Ventham, et al.
Alimentary Pharmacology & Therapeutics|February 24, 2011
A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel diseaseR K Russell, M L Wilson, S Loganathan, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Mucosal Immunology|April 13, 2017
MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammationG-T Ho, R E Aird, B Liu, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)G T Ho, A Mowat, L Potts, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2009
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-upC W Lees, A I Ali, A I Thompson, et al.
Journal of Crohn'S & Colitis|November 17, 2020
Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel diseaseR Kalla, A T Adams, D Bergemalm, et al.
Journal of Crohn'S & Colitis|June 30, 2020
Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel DiseaseR Kalla, A T Adams, N T Ventham, et al.
Alimentary Pharmacology & Therapeutics|February 24, 2011
A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel diseaseR K Russell, M L Wilson, S Loganathan, et al.
Pageof 4